Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8602057 | 0.97 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL13391635 | 0.80 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL10785234 | 0.80 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL9441831 | 0.80 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL7558647 | 0.79 | CYP3A4 (0.39) | CYP3A4TDP1ESR1ESR2TP53 | |
| Pyridine SCHEMBL11211408 | 0.79 | KDM4E (0.35) | CYP3A4TDP1TSHRKDM4EGAA | |
| Bromide SCHEMBL493074 | 0.76 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| Iodide SCHEMBL491999 | 0.76 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL9492996 | 0.76 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2TP53 | |
| SCHEMBL15658057 | 0.76 | ACHE (0.42) | TDP1LMNATSHRALOX12ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051294-A1 | NANOCRYSTAL PHOTORESIST-FREE PHOTOLITHOGRAPHIC METHOD BASED ON ORGANOPHOSPHORUS LIGAND | 南京大学 | 2025-03-13 | — | — | WO | claimed |
| CN-117420729-A | Nano crystal photoresist-free photoetching method based on organophosphorus ligand | 南京大学 | 2024-01-19 | — | — | CN | claimed |
| WO-2025051294-A1 | NANOCRYSTAL PHOTORESIST-FREE PHOTOLITHOGRAPHIC METHOD BASED ON ORGANOPHOSPHORUS LIGAND | 南京大学 | 2025-03-13 | — | — | WO | disclosed |
| CN-117420729-B | Application of nano crystal based on organophosphorus ligand in optical patterning | 南京大学 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024098840-A1 | ISOBUTYLENE-BASED CATIONIC SALT POLYMER, PREPARATION METHOD THEREFOR, USE THEREOF, AND ANTIBACTERIAL POLYMER MATERIAL | 中国石油化工股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| CN-117420729-A | Nano crystal photoresist-free photoetching method based on organophosphorus ligand | 南京大学 | 2024-01-19 | — | — | CN | disclosed |
| EP-2735581-B1 | COMPOSITION AND POLYMER | ASAHI CHEMICAL IND (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-109912586-A | The manufacturing method of inner mold -9- azabicyclo [ 3.3.1 ] nonane -3- 01 derivatives | 日本曹达株式会社 | 2019-06-21 | — | — | CN | disclosed |
| CN-105754099-B | Composition and polymer | 旭化成株式会社 | 2018-09-18 | — | — | CN | disclosed |
| US-10016749-B2 | Catalyst composition for hydrogenation and method for hydrogenation using the same | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9896451-B2 | Method for producing endo-9-azabicyclo[3.3.1]nonan-3-ol derivative | NIPPON SODA CO., LTD. (JP) | 2018-02-20 | — | — | US | disclosed |
| EP-0052930-A1 | Novel group VA salts and process for preparing same | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-06-02 | — | — | EP | disclosed |
| EP-0046628-A2 | Process for the preparation of nickel ylides containing directly sulfonated ylide ligands | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-03-03 | — | — | EP | disclosed |
| EP-0046332-A2 | Process for the preparation of nickel ylides containing ylide ligands with a sulfonated group V component | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4310716-A | NICKEL YLIDE CATALYST | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4301318-A | OBTAINED BY REACTING ETHYLENE USING A NICKEL YLIDE CATALYST; SOLVENT EXTRACTION OF CATALYST USING AMMONIUM HYDROXIDE | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1981-11-17 | — | — | US | disclosed |
| US-4293727-A | CATALYSIS WITH NICKEL YLIDE | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4293502-A | CATALYST FOR OLIGOMERIZATION OF ETHYLENE | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| EP-0003897-A1 | Phosphinegold(I)salts, process for their preparation and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-09-05 | — | — | EP | disclosed |
| US-4096250-A | ANTI-ARTHRITIC | SMITHKLINE CORPORATION (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016749-B2 | Catalyst composition for hydrogenation and method for hydrogenation using the same | H1-0, H1-2, HVCN1 | CYP3A4 1900/4885TDP1 3602/4885ESR1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.